Nanokine (epoetin alfa biosimilar) / Nanogen Biopharma - LARVOL DELTA

EPO: Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company (clinicaltrials.gov) - P1 | N=44 | Not yet recruiting | Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company

New P1 trial

Analytical-Based Methodologies for Examining the In Vitro Absorption, Distribution, Metabolism, and Elimination (ADME) of Silver Nanoparticles. (PubMed, Small) - "The clinical applications of silver nanoparticles (AgNPs) remain limited due to the lack of well-established methodologies for studying their nanokinetics...Metabolism: Cloud point extraction (CPE)-tangential flow filtration (TFF) reveal that ≤ 11% ± 4% of the administered, sublethal AgNPs release Ag(+) and contribute to the observed cytotoxicity. Elimination: ICP-OES-CPE suggests that AgNPs are cleared via exocytosis."

Journal